A natural solution to deliver medicine to the brain !

biOasis.ca!

OTCQX: BIOAFTSX.V: BTI

QUARTER 1 !

2015!

Forward Looking Statements

Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information.

Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com.

2"

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

Central Nervous System Diseases

3"

1)  (2012). Brain Facts; A Primer on the Brain and Nervous System . Publication, Society for Neuroscience. 2)  (2007). Neurological disorders: Public health challenges . Study, UN World Health Organization . 3)  bcc Research . (2010, September ). Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets, PHM068A.

AFFECT 1 IN 6 PEOPLE !

ALL TREATMENTS HINDERED BY THE BLOOD BRAIN BARRIER !

CNS diseases account for 12% of global

deaths1

Incidence of CNS diseases will increase by

12% by 20301

Over 1000 different CNS diseases with drugs hindered by BBB2

Total cost of CNS diseases is over $500 billion in USA alone2

CNS disease market is over $81.2 billion US

and rising3

"Challenge " The Blood Brain Barrier (“BBB”) A protective barrier that separates the brain from the circulatory system, which blocks harmful chemicals from entering the brain tissue

Problem The BBB prevents medicines (anti-cancer drugs, enzymes, antibodies, gene silencing siRNA, etc.) from entering the brain at levels effective for treatment, blocking about: •  98% of small molecule drugs •  100% of large molecule drugs1

Solution biOasis has discovered a naturally occurring biological process that can transport drugs across the BBB and into the brain tissue for the treatment of thousands of CNS diseases and brain disorders

4"

1)  Royal Society of Chemistry

Capillary network of tightly woven endothelial cells lining the blood vessels in the brain,

regulating transport of essential molecules and maintaining a stable environment

biOasis Presents: The Transcend Program

The Transcend Drug Delivery Platform

5"

Brain Cancers & Tumours

MetabolicDiseases like

Lysosomal Storage Diseases

Neurodegenerative Diseases like

Alzheimer's Disease

Stroke and Traumatic Brain

Injury

Gene Silencing Therapy for ALS

Patented carriers that deliver medicines across the BBB for the treatment of CNS diseases Transcend offers potential treatments for: "

MTfp (MTf peptide)

•  biOasis has discovered the peptide found within the full-length protein (MTf) that is responsible for transport of MTf across the BBB

•  MTfp has shown improved brain penetration and greater commercial potential over the full-length MTf protein

Breakthrough Solution

MTf (Melanotransferrin) •  Iron-binding human protein found at low concentrations in

the blood •  When linked to existing drugs, MTf can deliver effective doses

of medicine into the brain, distributing the medicine with a wide distribution throughout the brain tissue

6"

The Transcend Program

Exploits a natural, biological process to deliver medicines into the brain tissue by linking pre-existing drugs to a human protein that freely crosses the BBB through receptors located on the brain capillary wall in a process called Receptor Mediated Transcytosis.

Advantage of MTfp

!  Higher commercial value over MTf !  More efficient delivery across the BBB !  Lower cost of production !  Greater consistency in manufacturing !  Improved quality control !  Simpler to link to medicines !  Transports a variety of compounds

with no apparent size limitation !  Extends biOasis patent portfolio for

additional ~20 years !  Pharmaceutical collaborators currently

licensing MTfp

7"

RMT!

MTfp in Action

MTfp

Therapeutic RMT -Receptor Mediated Transcytosis

Brain Tissue

Blood Vessels

Market Opportunities for Transcend

2014 Drug Market Estimates

8"

A carrier to cross the BBB would establish a foothold within these major markets

Central Nervous

System Disorders

!

Stroke & Traumatic Brain Injury Infection

Lysosomal !Storage Disease !

~$20 Billion �USD

~$81.2 Billion �USD

~$7.5 Billion �USD

~$2 Billion �USD

~$33.7 Billion �USD

~$138 Billion �USD

~$32.3 Psychiatry Billion �

USD Neurodegenerative

Disease" Clinical need met but

improved BBB

penetration could

increase efficacy

Pain & Migraine "

Brain Cancer Drugs 2013 drug sales for cancers that frequently metastasize in the brain1

9"

1)  Company Reported Data

Herceptin® (trastuzumab) HER2+ Breast Cancer ~40% Metastasize

Taxol® (Paclitaxel) Lung, ovarian, etc. ~35% Metastasize

Rituxan® (Rituximab) Blood cancers: lymphoma, leukemia ~24% Metastasize

Erbitux® (Cetuximab) Lung. colon cancer, etc. ~35% Metastasize

$6.6 Billion �USD

$7.5 Billion �USD

$1.9 Billion �USD

$92 Million �USD

Improved cancer treatments have

led to an increase in brain tumours, creating a need for anti-cancer

drugs that target the brain

Anti-cancer drugs linked to MTf penetrate

the blood tumour barrier 10 times more

efficiently

The Transcend Program has been shown to reduce

brain tumour volume by 84%

when anti-cancer drugs are linked to

MTf

Business Opportunities

10"

Patent Cliff Estimated ~$250 billion in lost

revenue from patent expirations from 2012-20151

"

1)  DeRuiter, J., & Holston, P. L. (2012, June 20). Drug Patent Expirations and the “Patent Cliff”. U.S. Pharm. 2012;37(6)(Generic suppl):12-20. 2)  (2007). Neurological disorders: Public health challenges . Study, UN World Health Organization . http://www.un.org/apps/news/story.asp?newsid=21689&cr=neurological#.U7iNnBa4klI 3)  (2012). Brain Facts; A Primer on the Brain and Nervous System . Publication, Society for Neuroscience.

Market Growth CNS Drug Market is the

second largest pharmaceutical segment behind oncology3

"

Unmet Medical Need Over 1000 CNS diseases and brain disorders with treatments hindered by drug delivery across the BBB2

"Offers potential patent extensions

to the pharmaceutical industry through New Chemical Entity

designation for many preexisting, patent-expiring drugs

Aid in the development of new therapies and revitalize dormant

candidates that are proven efficacious but do not cross the

BBB

Expand the CNS drug market by opening up an industry that has

been heavily stagnated by ineffective drug delivery to the

brain

Management

Board of Directors Rob Hutchison, Chair & CEO Former: CEO & Chief Scientist at eCharge Corporation (One of the world’s first internet banking system) Chris Fibiger, PhD Former: Head of Neuroscience, Amgen; VP Neuroscience, Eli Lily & CSO, Biovail Laboratories Greg Gubitz, LLB Former: VP, Biovail Corporation & COO, MDS Capital Terry Pearson, PhD Professor: Biochemistry & Microbiology, UVIC Ron Erickson Current: Chair & CEO, Visulant Technologies Michael Hutchison, QC, LLB Current: Partner, Smith Hutchison Law Corporation

Team Judi Dalling, LLB, CFO Seasoned public company CFO and corporate lawyer Wilfred Jefferies, PhD, Founding Scientist Discovered MTf’s ability to cross the BBB Professor: Microbiology & Immunology, UBC Reinhard Gabathuler, PhD, Chief Scientist Former: VP Brain Research, Biomarin & CSO, Angiochem Inc. Mei Mei Tian, PhD, Scientist UBC, Microbiology and Immunology (MTf expert) Laura Ho, MSc, Scientist UBC, Microbiology and Immunology Tiffany Tolmie, Corporate Communications Honours, Wilfrid Laurier University

Obtain independent,

3rd party validation of MTf & MTfp

Expand & protect

intellectual property portfolio

Advance internal

development programs at

UBC

Collaborate with reputable pharmaceutical companies & institutions

Corporate Strategy

12"

•  Successful delivery of over 12 therapeutic compounds and over 6 imaging agents to the brain (enzymes, antibodies, small molecule drugs & biological agents)

•  Potential to achieve major, near-term milestones

•  Many “shots on goal” leading to commercial transactions with numerous licensees

•  Collaborations with large pharmaceutical partners "

•  Over 30 patents granted for blood-brain barrier drug delivery and neurodegenerative diseases

•  Strong pending patent portfolio

•  Over 20 year patent protection on MTfp

•  National Research Council

•  BC Cancer Research Centre

•  Texas Tech University Health Sciences Center

•  Southern Research Institute

•  University of Alabama

Strategic Collaborations

The Transcend Program

13"

AbbVie (Abbott Labs: ABT )

Research Agreement

UCB Pharmaceuticals (UCB)

Research Agreement

Brains for Brain Foundation

Research Agreement

MedImmune (AstraZeneca: AZN)

Licensing Agreement

Ongoing discussions with large pharmaceutical companies on licensing and research agreements.

MTfp

MTf

MTf: Rate of Uptake in Brain

14"

Compound Kin (x10-6; mL-1/s-1/g-1)

Reference

Glucose 9500 Smith (2003)

Melanotransferrin (MTf) 640 biOasis’ Transcend Program is the only drug delivery platform that utilizes a natural process to deliver drugs into the brain1

Morphine 200 Cisternino et al. (2001) Aprotinin 160 Angiochem in Stage 2 Clinical Trials2 Insulin Rec Antibody 100 ArmaGen licensing to Shire (2014)3 Leu-Enkephalin 60 Zlokovic (1987) Morphine-6-Glucuronide 24 Temsamani et al. (2005) RAP 10 Raptor Therapeutics – Licensing Issues4 Beta Amyloid 6.5 Banks (1991) DADLE 6.5 Chen (2002) TNF-α 4.3 Pan (2002)

Transport Efficiency !

More

Less

Compounds that freely cross the BBB compared to MTf

Com

petito

rs

1)  Demeule et al. (2002) 2)  Demeule et al. (2008) 3)  Pardridge (1997) 4)  Pan (2004)

Development Program: "biOasis’ MTf + Anti-Aβ antibody

Results biOasis’ MTf + anti-Aβ antibody conjugate increases transport into brain tissue by ~5-fold

Quantitative Image Analysis by Laser Scanning Confocal Microscopy

15"

Alzheimer’s Disease Anti-Aβ antibodies have undergone clinical trials for treatment of Alzheimer’s disease Opportunity Using antibodies directed at Aβ are potential therapeutics for reducing amyloid plaques in the brain, which are indicative of Alzheimer's disease

National Research Council of Canada (NRC)

Anti-Aβ MTf + Anti-Aβ

Development Program:"biOasis’ MTf + α-L-iduronidase (“IDU”)

Lysosomal Storage Diseases Rare inherited metabolic diseases caused by an enzyme deficiency primarily affecting children

Hurler Syndrome (MPS I) Problem •  MPS I is caused by an IDU enzyme deficiency •  Currently CNS effects untreatable

Results •  biOasis’ MTf + IDU (lysosomal enzyme)

conjugate increased IDU brain enzyme activity ~ 4-fold, showing delivery to the brain tissue

Opportunity •  Offers the promise of an efficient enzyme

replacement therapy

16"

0"

0.2"

0.4"

0.6"

0.8"

1"

1.2"

IDU MTf - IDU To

tal I

DU a

ctiv

ity Capillaries

Parenchyma

IDU Brain Enzymatic Activity !

Development Program:"biOasis’ MTf + iduronate-2-sulfatase (“IDS”)

Hunters Syndrome (MPS II) •  Lysosomal Storage disease, MPS II is caused

by an IDS enzyme deficiency •  Currently CNS effects untreatable Results •  biOasis’ MTf + IDS (lysosomal enzyme)

conjugate increased IDS brain enzyme activity ~20-fold, showing delivery to the brain tissue Opportunity •  Brains for Brain Foundation are in studies with

MTfp + IDS, which offers the opportunity to fast-track to human trials

•  Offers promise of an efficient enzyme replacement therapy

17"

MTf + IDS Enzyme enters the brain tissue

Native Enzyme does not enter the brain tissue efficaciously

Development Program: "biOasis’ MTf + Doxorubicin

•  Doxorubicin is currently used as a cancer treatment for breast, lung, ovarian, thyroid and stomach cancers; multiple myeloma, leukemia, Hodgkin's lymphoma, etc.

Problem •  These cancers metastasize in the brain but

Doxorubicin does not efficiently penetrate the BBB

Results •  Significant INCREASE in brain uptake with the

MTf + Doxorubicin conjugate vs. Doxorubicin alone

Opportunity •  MTf + Doxorubicin conjugate could be used to

treat brain cancers that metastasize in the brain 18"

0.00"

1.00"

2.00"

3.00"

MTf + DOXO DOXO

% INJECTED DOSE (G TISSUE/G BODY MASS)*100%

MTf Significantly Enhances Doxorubicin Transport into the Brain

Conjugate retains full activity once released in the brain

MTf Reduces Doxorubicin Uptake in the Heart Problem •  Doxorubicin’s most serious adverse

effect is life-threatening heart damage

Results •  biOasis’ MTf + Doxorubicin vs.

Doxorubicin on its own showed a significant DECREASE in uptake in the heart

Opportunity •  Could be used to treat brain

cancers and decrease heart-uptake side effect, offering increased usage of Doxorubicin for brain cancer treatment

19"

0.0"

5.0"

10.0"

15.0"

20.0"

% IN

JEC

TED

DO

SE

(gra

m b

rain

tiss

ue/g

ram

bod

y m

ass)

*100

MTf + DOXO DOXO

Development Program: "biOasis’ MTf + Trastuzumab (Herceptin®)

•  Trastuzumab (Herceptin®)1 is a humanized monoclonal antibody used to treat HER2+ breast cancer with annual global sales ~$6.6 billion2

•  Herceptin® increases survival rate but ~40% of patients eventually develop breast cancer metastasis in the brain3

•  Trastuzumab (Herceptin®) does not cross the BBB on its own

•  biOasis aims to, not only prevent and treat HER2+ breast cancer that metastasizes in the brain, but also for Transcend to become the ‘Standard of Care’ for HER2+ breast cancer

20"

1)  Herceptin® is a registered trademark of Roche/Genentech 2)  Company Reported Data – 2013 3)  Britta Weigelt, Johannes L. Peterse & Laura J. van't Veer. (2005, August). Breast cancer metastasis: markers and models. Nature Reviews

Cancer 5 , 591-602.

Brain Capillaries

Cell Nuclei

MTf + Trastuzumab (Herceptin®)

Confocal Image Performed by iCapture at St. Paul’s Hospital Vancouver Canada

MTf + Trastuzumab (Herceptin®) Confocal Images Two Hours Post IV Administration

MTf + Trastuzumab (Herceptin®) "Texas Tech University - Breast Cancer Model

21"

0"10"20"30"40"50"60"70"80"90"

MTf TZM MTf-TZM Saline Control !

Number of Tumours Highlights •  Reduced the number of HER2+ breast

cancer tumours in the brain by 68% •  Total tumor volume reduced by 84% in

only 14 days, after 4 treatments •  Penetrated the Blood-Tumour Barrier

10 times better than Herceptin® alone •  Increased cancer killing effect of

Herceptin® in tumours throughout the body when linked with MTf

•  Offers the potential to be used in conjunction with HER2+ cancer therapy as a treatment and preventative measure BEFORE the cancer metastasizes to the brain

68% Reduction

TZM = Trastuzumab (Herceptin®)

Development Program: "MTfp + siRNA

Small Interfering RNA (siRNA) •  Silences target gene expression by knocking down disease

causing genes associated with human diseases (i.e. cancers, neurodegenerative and metabolic diseases, etc.)

Problem •  Gene targeting within the brain is currently unachievable because

siRNA does not cross the BBB

Results •  MTfp + siRNA conjugate delivered into the brain tissue •  Demonstrated 40% to 50% decrease in target gene vs. siRNA

alone

Opportunity •  A potential cornerstone technology for the development of new

therapeutics suppressing disease-linked genes in the brain •  siRNA is a rapidly emerging field of medicine

22"National Research Council

NO siRNA detected in Brain

MTf + siRNA detected in Brain

Pipeline

23"

Brain Transport

Quantity in the Brain

Localization in Brain (Cellular)

Efficacy Models

Brain Cancer Herceptin: Breast Cancer

Lysosomal Storage Disease Hunters Syndrome: MPS II Model

Sandhoff Disease: Hex B Model

siRNA Stroke Model A

ALS Model B

Market Profile "

24"

Data source: S&P Capital IQ

TSX.V:BTI; OTCQX:BIOAFShares Issued & Outstanding 44,034,257

Fully Diluted 52,073,734

Options 6,095,000 Directors, officers & employees

Warrants 1,944,477 IP Warrants

Market Cap ~$52.8m @ $1.20 Share Price (Feb. 2, 2015)

Cash Position ~$2,095,329

Ownership Insiders & Affiliates ~35% Institutional ~10%

Summary

25"

!Intellectual Property

& Collaborations

Strong patent protection Patent portfolio of >30 patents

Large pharmaceutical collaborations

Positive results; successful demonstration

Large Market Opportunities

Ability to extend patent life Commercialize new therapeutics

and/or revitalize dormant candidates

Contribute to the growth in CNS drug market

"

Treatment Potential

Metabolic diseases Neurodegenerative

diseases Brain Cancer

"

Awarded TSX.V Top 50® in 2013

Leader in providing shareholder value

Market Profile

Good cash position Clean share structure Exit strategy in place

High internal ownership

Management

Major success in: Drug commercialization Biotechnology & venture

capital startups Academia

"

Transcend Program

“The first natural carrier to effectively

transport therapeutic drugs into the brain.”

Discovery of MTfp

Enhanced technology Greater commercial

potential "